Description
Prostaglandin J2-d4 is intended for use as an internal standard for the quantification of prostaglandin J2 by GC- or LC-MS. Prostaglandin J2 (PGJ2) is formed from PGD2 by the elimination of the C-9 hydroxyl group, a process which is accelerated by the presence of albumin.1 PGJ2 inhibits platelet aggregation with an IC50 of about 5-10 nM.2,3 PGJ2 has antimitotic and antiproliferative effects on a variety of cultured normal cells and tumor cell lines.4 However, this activity has been attributed to further metabolites of PGJ2 and not the parent compound itself.
References
1. Fitzpatrick, F.A., and Wynalda, M.A. Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro J. Biol. Chem. 258(19),11713-11718(1983).
2. Bundy, G.L., Morton, D.R., Peterson, D.C., et al. Synthesis and platelet aggregation inhibiting activity of prostaglandin D analogues J. Med. Chem. 26(6),790-799(1983).
3. Mahmud, I., Smith, D.L., Whyte, M.A., et al. On the identification and biological properties of prostaglandin J2 Prostaglandins Leukot. Med. 16(2),131-146(1984).
4. Fukushima, M. Prostaglandin J2 - anti-tumor and anti-viral activities and the mechanisms involved Eicosanoids 3(4),189-199(1990).
